- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06061523
A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants
A Phase I, Open-label, Randomized Crossover Study to Evaluate the Relative Bioavailability and the Effect of Food for Sotorasib Tablets in Healthy Participants
Study Overview
Study Type
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy male or female participants, between 18 and 60 years of age (inclusive), at the time of Screening.
- Body mass index, between 18 and 32 kg/m2 (inclusive), at the time of Screening
- Females of nonchildbearing potential
- In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable) as assessed by the Investigator (or designee).
Exclusion Criteria:
- Inability to swallow oral medication or history of malabsorption syndrome.
- History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
- Poor peripheral venous access.
- History or evidence, at Screening or Check in, of clinically significant disorder, condition, or disease, including not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
- History or evidence of clinically significant arrhythmia at Screening, including any clinically significant findings on the ECG taken at Check-in.
- History suggestive of esophageal (including esophageal spasm, esophagitis), gastric, or duodenal ulceration or bowel disease (including but not limited to peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's disease, or irritable bowel syndrome), or a history of gastrointestinal surgery other than uncomplicated appendectomy and hernia repair. History of cholecystectomy is not permitted.
- Estimated glomerular filtration rate (eGFR) less than 70 mL/min/1.73 m² as calculated by the Modification of Diet in Renal Disease (MDRD) equation, at Screening or Check-in.
- ALT or AST > ULN, at Screening or Check-in.
- Thyroid-stimulating hormone outside normal range.
- Positive hepatitis B or hepatitis C panel and/or positive human immunodeficiency virus test, at Screening. Participants whose results are compatible with prior immunity (vaccination or prior infection) may be included.
- Use of any over-the-counter or prescription medications within 30 days or 5 half-lives (whichever is longer) before enrollment. Acetaminophen (paracetamol) (up to 2 g per day) for analgesia will be allowed. Hormone-replacement therapy (e.g., estrogen) will be allowed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Sequence ABC
Participants will be administered sotorasib orally in the following order: Treatment A - as 4 tablets under fasting conditions (test) Treatment B - as 8 tablets under fasting conditions (reference) Treatment C - as 4 tablets under fed conditions (test) |
Oral Tablet
Other Names:
|
Experimental: Treatment Sequence BAC
Participants will be administered sotorasib orally in the following order: Treatment B - as 8 tablets under fasting conditions (reference) Treatment A - as 4 tablets under fasting conditions (test) Treatment C - as 4 tablets under fed conditions (test) |
Oral Tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum Plasma Concentration (Cmax) of Sotorasib
Time Frame: Approximately 9 days
|
Approximately 9 days
|
Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib
Time Frame: Approximately 9 days
|
Approximately 9 days
|
Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Sotorasib
Time Frame: Approximately 9 days
|
Approximately 9 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants who Experience a Treatment-emergent Adverse Event (TEAE)
Time Frame: Approximately 9 days
|
Approximately 9 days
|
Number of Participants who Experience a Serious Adverse Event (SAE)
Time Frame: Up to approximately 39 days
|
Up to approximately 39 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: MD, Amgen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20220098
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
Insmed IncorporatedRecruitingHealthy ParticipantsUnited States
-
Aeovian Pharmaceuticals, Inc.RecruitingHealthy ParticipantsAustralia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingHealthy ParticipantsChina
-
CelgeneNot yet recruitingHealthy ParticipantsUnited States
-
Bristol-Myers SquibbRecruiting
-
AstraZenecaParexelRecruiting
-
ProMis Neurosciences, IncRecruiting
-
Novo Nordisk A/SRecruitingHealthy ParticipantsCanada
-
Novo Nordisk A/SRecruiting
Clinical Trials on Sotorasib
-
Yonsei UniversityNot yet recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingNon Small Cell Lung Cancer | KRAS P.G12CFrance
-
Revolution Medicines, Inc.Sanofi; AmgenActive, not recruitingNon-Small Cell Lung CancerUnited States, Korea, Republic of, Canada, Taiwan, Spain, United Kingdom, Italy, Australia, France, Germany
-
Southwest Oncology GroupNational Cancer Institute (NCI)RecruitingLung Adenocarcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Squamous Non-Small Cell CarcinomaUnited States, Guam
-
Vestre Viken Hospital TrustOdense University Hospital; Karolinska University Hospital; Oslo University Hospital and other collaboratorsRecruitingCancer | Lung Cancer | NSCLC Stage IV | Mutation | NSCLC, Stage III | Lung Cancer Stage IV | Cancer, LungNorway
-
Navire Pharma Inc., a BridgeBio companyAmgenRecruitingNon Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Metastatic NSCLCSpain, Australia, France, Denmark, Greece, Italy, Netherlands
-
Vitrac Therapeutics, LLCWestatTerminatedNon-small Cell Lung CancerUnited States
-
Verastem, Inc.AmgenRecruitingNon Small Cell Lung Cancer | KRAS Activating MutationUnited States, United Kingdom, Netherlands, Belgium
-
Medical University of South CarolinaRain Oncology IncTerminated
-
Fox Chase Cancer CenterWithdrawnNon-Small Cell Lung CancerUnited States